Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Cost of Revenue (2016 - 2025)

IGC Pharma (IGC) has disclosed Cost of Revenue for 16 consecutive years, with $92000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cost of Revenue fell 57.01% to $92000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $595000.0, a 14.86% increase, with the full-year FY2025 number at $652000.0, up 6.54% from a year prior.
  • Cost of Revenue was $92000.0 for Q3 2025 at IGC Pharma, down from $174000.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $300000.0 in Q2 2023 to a low of $18000.0 in Q3 2021.
  • A 5-year average of $118736.8 and a median of $102000.0 in 2023 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: plummeted 90.52% in 2021, then surged 328.57% in 2023.
  • IGC Pharma's Cost of Revenue stood at $80000.0 in 2021, then skyrocketed by 187.5% to $230000.0 in 2022, then plummeted by 69.13% to $71000.0 in 2023, then soared by 115.49% to $153000.0 in 2024, then plummeted by 39.87% to $92000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Cost of Revenue are $92000.0 (Q3 2025), $174000.0 (Q2 2025), and $176000.0 (Q1 2025).